Table II.
Descriptive Data for All Hypertensive Patients and Diabetic and Nondiabetic Subgroups
| All Hypertensives | Diabetic Hypertensives | Nondiabetic Hypertensives | ||||
|---|---|---|---|---|---|---|
| African | African | African | ||||
| Caucasian | American | Caucasian | American | Caucasian | American | |
| n | 25,987 | 15,930 | 8041 | 6230 | 17,946 | 9700 |
| VA (%) | 47.4 | 43.8 | 56.5 (56.3–56.6)* | 46.7 | 43.4 | 42.0 |
| (47.3–47.6)* | (43.7–44.0) | (46.6–46.9) | (43.3–43.6)* | (41.8–42.1) | ||
| Age (yr) | 65.0 (64.8–65.1)* | 61.6 (61.4–61.8) | 67.2 (67.0–67.5)* | 64.0 | 64.0 | 60.1 |
| (63.7–64.3) | (63.8–61.2)* | (59.8–60.4) | ||||
| Sex (M/W [%]) | 68/32 | 58/42 | 75/25 | 60/40 | 66/34 | 57/43 |
| BP (mm Hg) | ||||||
| Systolic BP | 135.7 | 138.8 | 136.0 | 139.8 | 135.5 | 138.2 |
| (137.1–137.4) | (138.5–139.1)* | (135.6–136.5) | (139.2–140.3)* | (135.3–135.8) | (137.8–138.6)* | |
| Diastolic BP | 76.8 | 80.1 | 74.2 | 78.0 | 77.9 | 81.5 |
| (76.6–76.9) | (79.9–80.3)* | (74.0–74.5) | (77.7–78.3)* | (77.8–78.1) | (81.3–81.7)* | |
| <130/80 | 27.0 | 21.3 | 30.7 | 23.1 | 25.3 | 20.1 |
| mm Hg (%) | (26.9–27.1)* | (21.2–21.4) | (30.6–30.9)* | (23.0–21.2) | (25.2–25.4)* | (20.0–20.2) |
| <140/90 | 55.3 | 48.1 | 55.9 | 48.0 | 55.0 | 48.1 |
| mm Hg (%) | (55.1–55.4)* | (47.9–48.2) | (55.8–56.1)* | (47.9–48.2) | (54.8–55.1)* | (48.0–48.3) |
| No. of BP medications (%) | ||||||
| 0 | 23.2 | 14.6 | 19.4 | 11.8 | 24.9 | 16.5 |
| (23.1–23.3)* | (14.5–14.7) | (19.2–19.6)* | (11.7–12.0) | (24.7–25.0)* | (16.3–16.6) | |
| 1 | 27.7 | 23.0 | 26.2 | 21.4 | 28.3 | 24.0 |
| (27.5–27.8)* | (22.8–23.1) | (26.0–26.5)* | (21.2–21.7) | (28.2–28.5)* | (23.8–24.1) | |
| 2 | 26.2 | 26.6 | 26.0 | 24.7 | 26.3 | 27.8 |
| (26.0–26.3) | (26.4–26.7)* | (25.8–26.2)* | (24.5–25.0) | (26.1–26.4) | (27.6–28.0)* | |
| 3 | 14.4 | 18.9 | 17.0 | 20.2 | 13.2 | 18.1 |
| (14.3–14.5) | (18.8–19.1)* | (16.8–17.1) | (20.0–20.4)* | (13.1–13.3) | (18.0–18.3)* | |
| ≥4 | 8.6 | 16.9 | 11.4 | 21.8 | 7.4 | 13.7 |
| (8.6–8.7) | (16.8–17.0)* | (11.3–11.5) | (21.6–22.0)* | 7.3–7.5) | (13.6–13.8)* | |
| No. of BP | 2.10 | 2.48 | 2.23 | 2.67 | 2.03 | 2.35 |
| medications (mean) | (2.08–2.11) | (2.45–2.50)* | (2.20–2.26) | (2.63–2.70)* | (2.01–2.05) | (2.32–2.38)* |
| ACEI±ARB | 58.8 | 61.9 | 69.4 | 77.7 | 53.6 | 51.2 |
| (%) | (58.6–58.9) | (61.7–62.1)* | (69.1–69.7) | (77.5–77.9)* | (53.4–53.8)* | (51.0–51.5) |
| ≥2 with | 44.9 | 52.6 | 53.1 | 64.1 | 41.0 | 44.7 |
| ACEI±ARB (%) | (44.7–45.1) | (52.3–52.8)* | (52.8–53.4) | (63.8–64.4)* | (40.7–41.2) | (44.5–45.0)* |
| VA=Veterans Affairs hospitals and clinics; M=men; W=women; BP=blood presure; ACEI=angiotensin‐converting enzyme inhibitor; ARB=angiotensin‐1 receptor blocker; *value significantly higher (p<0.05) for within‐group ethnic comparison; parentheses indicate 95% confidence intervals | ||||||